Detail of "27821-45-0"

Reference

Treating alcoholism with disodium uridine 5'-diphosphate

Treating alcoholism with disodium uridine 5'-diphosphate. Hata, Shunichi; Mizuno, Koji; Nishii, Yasuho; Mitsuishi, Etsuko; Shiba, Motoharu (Chugai Pharmaceutical Co., Ltd., Japan). U.S. US 4058601 15 Nov 1977, 5 pp. (English). (United States of America). CODEN: USXXAM. CLASS: IC: A61K031-70. NCL: 424180000. PRIORITY: JP 74-78732 7 Nov 1974. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Pharmaceutical compns. that decrease blood alc. levels and inhibit accumulation of neutral lipids in the liver contain di-Na uridine 5-diphosphate (I di-Na salt)(II) [27821-45-0]. Thus, rats treated with 100 mg II/kg and 30 min thereafter with EtOH [64-17-5] at 6 g/kg exhibited 1.51 mg/mL EtOH level in blood after 4.5 h compared to 3.05 mg/mL for control rats administered saline and EtOH in place of II and EtOH. Capsules were prepd. contg. 300 mg II each.

Production and properties of di(uridine 5')-tetraphosphate and its salts

Production and properties of di(uridine 5')-tetraphosphate and its salts. Yerxa, Benjamin R.; Brown, Edward G. (USA ). U.S. Pat.Chemicals with cas numbers 27821-45-0 and 546-89-4 also play role. Appl. Publ. US 2004014713 A1 22 Jan 2004,13 pp., Cont.-in-part of U.S. Ser. No. 990,546. (English). (United States of America). CODEN: USXXCO. CLASS: ICM: A61K031-7072. ICS: C07H019-207. NCL: 514051000; 536026220. APPLICATION: US 2003-413965 14 Apr 2003. PRIORITY: US 1997-PV54147 25 Jul 1997; US 1998-122516 24 Jul 1998; US 2001-990546 20 Nov 2001. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1, 29, 45 The present invention is directed to P1,P4-di(uridine-5')-tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1, P4-di(uridine-5')-tetraphosphate are water-sol., nontoxic, and easy to handle during manuf. These tetra-monovalent alkali metal salts are more resistant to hydrolysis than the mono-, di-, or tri-acid salts, therefore, they provide an improved stability and a longer shelf life for storage. The present invention also provides methods for the synthesis of P1,P4-di(uridine-5')-tetraphosphate, and its pharmaceutically acceptable salts, and demonstrates the applicability to the prodn. of large quantities. The methods substantially reduce the time required to synthesize diuridine tetraphosphate, for example, to three days or less. A sterile pharmaceutical formulation contg. P1,P4-di(uridine-5')-tetraphosphate or its salt is also provided. .